NCT04613596 2026-03-18
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Phase 2/3 Recruiting
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
BioNTech SE
AbbVie
Bristol-Myers Squibb
Cancer Research UK
AbbVie